Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 4/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5568 | 0.70 | NISCH (0.38) | NISCHADRA2AADRA2BADRA2CCYP1A2 | |
| SCHEMBL519700 | 0.68 | NOS2 (0.39) | NISCHCYP1A2SMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL7873570 | 0.68 | NISCH (0.34) | NISCHADRA2AADRA2BADRA2CMAOA | |
| SCHEMBL516458 | 0.67 | SMN1; SMN2 (0.41) | CYP1A2SMN1; SMN2MEN1ALDH1A1GAA | |
| SCHEMBL516862 | 0.67 | NISCH (0.36) | NISCHADRA2AADRA2BADRA2CCYP1A2 | |
| SCHEMBL5320061 | 0.67 | CYP1A2 (0.31) | CYP1A2SMN1; SMN2 | |
| SCHEMBL29429214 | 0.65 | ACHE (0.37) | — | |
| SCHEMBL5233554 | 0.65 | ACHE (0.37) | — | |
| SCHEMBL157325 | 0.65 | — | — | |
| SCHEMBL29550114 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 365 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2909212-B1 | SUBSTITUTED 1,4-DIHYDROPYRAZOLO[4,3-B]INDOLES | TAKEDA PHARMACEUTICALS CO (JP) | 2017-02-22 | — | — | EP | claimed |
| US-9475816-B2 | Substituted-1,4-dihydropyrazolo[4,3-b]indoles | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-25 | — | — | US | claimed |
| US-9434743-B2 | Indazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-09-06 | — | — | US | claimed |
| US-20150225405-A1 | SUBSTITUTED-1,4-DIHYDROPYRAZOLO[4,3-b]INDOLES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-13 | — | — | US | claimed |
| US-20150005232-A1 | INDAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2015-01-01 | — | — | US | claimed |
| WO-2013130855-A1 | INDAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-09-06 | — | — | WO | claimed |
| US-20240239790-A1 | 7-Morpholino-1,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor | LIFEARC (GB) | 2024-07-18 | — | — | US | disclosed |
| WO-2024149990-A1 | NIRMATRELVIR ANALOGS AS 3C LIKE PROTEASE INHIBITORS FOR TREATING VIRAL INFECTIONS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2024-07-18 | — | — | WO | disclosed |
| CN-118317949-A | Isoindolines as PMS2 inhibitors | 奈奥芬莱有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-118317954-A | Indoline as PROTAC compound | 奈奥芬莱有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-118307515-A | Antibacterial compounds | 英菲克斯治疗有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-118317950-A | Sulfonamide compounds for the treatment of neurological disorders | 拉里奥治疗有限公司 | 2024-07-09 | — | — | CN | disclosed |
| EP-3628045-B1 | COMPOUNDS | UNIV SHEFFIELD (GB) | 2024-07-03 | — | — | EP | disclosed |
| US-20090209524-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-08-20 | — | — | US | disclosed |
| WO-2009067081-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ASTHMA, COPD, ALLERGIC RHINITIS, ALLERGIC CONJUNCTIVITIS, ATOPIC DERMATITIS, CANCER, HEPATITIS B, HEPATITIS C, HIV, HPV, BACTERIAL INFECTIONS AND DERMATOSIS | ASTRAZENECA AB (SE) | 2009-05-28 | — | — | WO | disclosed |
| US-20090062267-A1 | L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-20080255183-A1 | N-[HETEROARYLCARBONYL]-3-THIENYL-L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| US-20080194572-A1 | 5,6,7,8-TETRAHYDROPTERIDINE DERIVATIVES AS HSP90 INHIBITORS | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | US | disclosed |
| US-20080182842-A1 | L-alanine derivatives as a5beta1 antagonists | ASTRAZENECA AB (SE) | 2008-07-31 | — | — | US | disclosed |
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239790-A1 | 7-Morpholino-1,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor | DCK, ERCC2, POLK | NISCH 4857/4885ADRA2A 4358/4885ADRA2B 4031/4885 |
| US-20080255183-A1 | N-[HETEROARYLCARBONYL]-3-THIENYL-L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS | ITGA2B, ITGB1, ITGB5 | NISCH 2389/4885ADRA2A 40/4885ADRA2B 22/4885 |
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ITGB5, ITGB1, ITGA2B | NISCH 3353/4885ADRA2A 40/4885ADRA2B 5/4885 |
| US-20150005232-A1 | INDAZOLE DERIVATIVES | GPR119, INSR, INSRR | NISCH 2213/4885ADRA2A 486/4885ADRA2B 528/4885 |
| US-20080194572-A1 | 5,6,7,8-TETRAHYDROPTERIDINE DERIVATIVES AS HSP90 INHIBITORS | HSP90AA1, HSP90AB1, HSP90AB2P | NISCH 133/4885ADRA2A 432/4885ADRA2B 499/4885 |
| US-20090209524-A1 | Novel Compounds | ABCG2, CYP4B1, CYP3A4 | NISCH 1180/4885ADRA2A 167/4885ADRA2B 107/4885 |
| US-20090062267-A1 | L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS | ITGA2B, ITGB1, ITGAL | NISCH 3363/4885ADRA2A 41/4885ADRA2B 26/4885 |
| US-20080182842-A1 | L-alanine derivatives as a5beta1 antagonists | ITGB1, ITGA2B, ITGB5 | NISCH 3338/4885ADRA2A 46/4885ADRA2B 28/4885 |
| US-20150225405-A1 | SUBSTITUTED-1,4-DIHYDROPYRAZOLO[4,3-b]INDOLES | GPR119, RPLP2, FOXM1 | NISCH 2274/4885ADRA2A 84/4885ADRA2B 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.